SCHEMBL249099

SCHEMBL249099

CCCCCOc1ccc(NC(=O)Nc2cccc3ccccc23)c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.61
CNR1 P21554 5/20 0.61
CYP2C9 P11712 1/20 0.61
EPHX1 P07099 1/20 0.55
KDM4E B2RXH2 4/20 0.52
KMT2A Q03164 4/20 0.52
ALDH1A1 P00352 4/20 0.52
HPGD P15428 3/20 0.52
MEN1 O00255 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
NPC1 O15118 1/20 0.50
MAPT P10636 1/20 0.50
MAPK14 Q16539 1/20 0.49
RAB9A P51151 2/20 0.49
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL249337 0.86 CNR1 (0.57) CNR2CNR1CYP2C9KMT2AMEN1
SCHEMBL27891629 0.79 PLK1 (0.59) CNR2CNR1CYP2C9MAPK14
SCHEMBL27891628 0.79 PLK1 (0.59) CNR2CNR1CYP2C9MAPK14
SCHEMBL10879439 0.77 ALDH1A1 (0.70) CNR2CNR1EPHX1KDM4EKMT2A
SCHEMBL9813593 0.77 ALDH1A1 (0.70) CNR2CNR1EPHX1KDM4EKMT2A
SCHEMBL14424459 0.77 EPHX1 (0.81) EPHX1KDM4EKMT2AALDH1A1MEN1
SCHEMBL249074 0.77 CNR2 (0.53) CNR2CNR1CYP2C9KMT2AMEN1
SCHEMBL29362406 0.76 CNR2 (1.00) CNR2CNR1CYP2C9KMT2AMEN1
SCHEMBL247361 0.76 CNR2 (1.00) CNR2CNR1CYP2C9KMT2AMEN1
SCHEMBL27875263 0.76 PLK1 (0.55) CNR2CNR1CYP2C9KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1339663-B1 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2012-01-04 EP disclosed
EP-2338886-A2 Naphthalene derivatives Novartis AG (CH) 2011-06-29 EP disclosed
US-7045533-B2 Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout NOVARTIS AG (CH) 2006-05-16 US disclosed
US-20040053890-A1 Naphthalene derivatives NOVARTIS AG (CH) 2004-03-18 US disclosed
EP-1339663-A2 NAPHTHALENE DERIVATIVES Novartis AG (CH) 2003-09-03 EP disclosed
WO-2002042248-A2 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053890-A1 Naphthalene derivatives CYP1A1, SULT1E1, CYP2F1 CNR2 86/4885CNR1 35/4885CYP2C9 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.